Skip to main content
Mithra Pharmaceuticals S.A. logo

Mithra Pharmaceuticals S.A. — Investor Relations & Filings

Ticker · MITRA ISIN · BE0974283153 LEI · 5493002FDD273HTEKK14 BR Manufacturing
Open in API
Filings indexed 754 across all filing types
Latest filing 2023-10-13 Proxy Solicitation & In…
Country BE Belgium
Listing BR MITRA

About Mithra Pharmaceuticals S.A.

https://www.mithra.com/

Mithra Pharmaceuticals S.A. is a biotech company dedicated to women's health. The company focuses on the development, manufacturing, and commercialization of differentiated drugs and complex therapeutic solutions. Its core areas of expertise include contraception, fertility, and menopause. Mithra aims to transform the women's health sector by providing innovative choices to support and improve the overall quality of life for women.

Recent filings

Filing Released Lang Actions
2023-10-13_MITHRA_EGM-SGM-OCTOBER-2023_REVISED-VOTING-BY-MAIL_EN.pdf
Proxy Solicitation & Information Statement Classification · 98% confidence The document is a 'REVISED VOTING BY MAIL' form for 'special and extraordinary general meetings of Mithra Pharmaceuticals SA to be held on 30th October 2023'. It details the agenda items, which include confirmation of director appointments, director remuneration, approval of a revised remuneration policy, ratification of financing agreements (Amended Agreements), and resolutions for the dismissal and appointment of directors. This material is explicitly designed to solicit shareholder votes for a general meeting and provides the necessary information for shareholders to cast their votes (either by mail or proxy). This aligns perfectly with the definition of Proxy Solicitation & Information Statement (PSI), which covers materials sent to shareholders to provide information and request votes for meetings. It is not the final declaration of results (DVA), nor is it the full Annual Report (10-K).
2023-10-13 English
2023-10-13_MITHRA_EGM-SGM-OCTOBER-2023_REVISED-AGENDA_FR.pdf
AGM Information Classification · 99% confidence The document is titled "ORDRE DU JOUR RÉVISÉ DES ASSEMBLÉES SPÉCIALE ET EXTRAORDINAIRE DES TITULAIRES DE TITRES DU 30 OCTOBRE 2023" (Revised Agenda for the Special and Extraordinary General Meetings of Security Holders of October 30, 2023). It explicitly details items to be voted upon at a general meeting, such as the confirmation of a director's appointment, changes to director remuneration, approval of a revised remuneration policy, ratification of financing agreements contingent on a change of control, and proposals to revoke and appoint directors. These elements are characteristic of materials prepared for a shareholder meeting, specifically focusing on governance and corporate actions requiring shareholder approval. This strongly aligns with the definition of materials related to an Annual General Meeting (AGM) or Extraordinary General Meeting, which falls under the AGM Information category (AGM-R). It is not a full Annual Report (10-K), an Earnings Release (ER), or a simple announcement of a report (RPA).
2023-10-13 French
2023-10-13_MITHRA_EGM-SGM-OCTOBER-2023_INDEPENDENCE-REQUIREMENTS_EN.pdf
Governance Information Classification · 98% confidence The document discusses a request from shareholders to add items to the agenda of a special general shareholders' meeting and then extensively details the independence requirements for a director candidate (Castors Development SA, represented by Jacques Platieau) based on the Belgian Corporate Governance Code 2020 and the Company's Corporate Governance Charter. This content directly relates to the structure, rules, and composition of the board and internal governance practices. This aligns best with the Governance Information (CGR) category, which covers internal rules, board structure, and governance practices, rather than a specific management change (MANG) or a proxy solicitation for voting (PSI). The document is substantive and explanatory, not just a brief announcement of a report.
2023-10-13 English
2023-10-13_MITHRA_EGM-SGM-OCTOBER-2023_REVISED-VOTING-BY-MAIL_FR.pdf
Proxy Solicitation & Information Statement Classification · 98% confidence The document is titled "VOTE PAR CORRESPONDANCE RÉVISÉ" (Revised Proxy Vote) and explicitly details the agenda and voting procedures for the "assemblées générales spéciale et extraordinaire" (Special and Extraordinary General Meetings) of Mithra Pharmaceuticals SA, scheduled for October 30, 2023. It contains specific proposals for shareholder votes, such as confirming the appointment of a director, approving remuneration policies, and ratifying financing agreements contingent on a change of control. This content is characteristic of materials sent to shareholders to solicit their votes ahead of a general meeting. The closest matching category is 'Proxy Solicitation & Information Statement' (PSI), which covers materials requesting shareholder votes. It is not the final results (DVA) nor the general AGM presentation (AGM-R).
2023-10-13 French
2023-10-13_MITHRA_EGM-SGM-OCTOBER-2023_REVISED-PROXY_EN.pdf
Proxy Solicitation & Information Statement Classification · 99% confidence The document is explicitly titled 'REVISED PROXY' and details instructions for shareholders on how to appoint a proxy holder to vote on their behalf at a 'Special and Extraordinary General Meetings' scheduled for October 30, 2023. It includes an agenda covering director replacement, remuneration, policy approval, financing agreement ratification (under Belgian law article 7:151), and dismissal/appointment of directors. This material is designed to solicit shareholder votes and provide necessary information ahead of a general meeting, which aligns perfectly with the definition of Proxy Solicitation & Information Statement (PSI). It is not the final voting result (DVA), the full annual report (10-K), or just an earnings announcement (ER).
2023-10-13 English
2023-10-13_MITHRA_EGM-SGM-OCTOBER-2023_INDEPENDENCE-REQUIREMENTS_FR.pdf
Governance Information Classification · 95% confidence The document discusses the addition of points to the agenda of a special general meeting of shareholders following a request from existing shareholders (6.15% ownership). It then transitions into a detailed annex concerning the independence requirements for directors, referencing the Belgian Corporate Governance Code 2020 and specific articles (7:87 CSA). This content—dealing with shareholder requisitions for meetings and detailed governance/director independence criteria—is highly characteristic of materials related to board structure, governance practices, and potentially proxy solicitation or meeting preparation. Since it focuses heavily on governance rules and director qualifications rather than just announcing a vote result (DVA) or being a general proxy statement (DEF 14A/PSI), the most fitting category is Governance Information (CGR), which covers internal rules and board structure.
2023-10-13 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.